Royalty Pharma Sub-Manager, LLC — 13F Holdings & Portfolio
CIK 2081668 · latest 13F-HR filed 2026-08-21
Royalty Pharma Sub-Manager, LLC manages $241.9M in 13F-reported U.S. long-equity assets across 4 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CYTK (34.52%), ZBIO (25.05%), KLRA (22.36%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 3, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 3300
NEW YORK, NY 10022
$241.9M
Long-equity book
4
Distinct positions
2026-06-30
Filed 2026-08-21
+1 / −1 / ↑3 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CYTOKINETICS, INC$18.9M +29.3%
- BIOHAVEN LTD$18.9M +75.9%
- ZENAS BIOPHARMA, INC.$13.9M +29.8%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-21 | $241.9M | 4 | 0002081668-26-000018 |
| 2026-03-31 | 2026-05-14 | $172.8M | 4 | 0002081668-26-000006 |
| 2026-03-31 | 2026-08-21 | $172.8M | 4 | 0002081668-26-000017 |
| 2025-12-31 | 2026-04-01 | $171.3M | 4 | 0002081668-26-000003 |